BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSGMedical - Healthcare Information Services
+$0.29 today
- Market cap
- $13.60B
- Beta
- 1.87
- P/E (TTM)
- 56.0
- EPS (TTM)
- $1.15
Volume 1.77M
Average 2.99M
BTSG Interest Income
Income earned on cash, deposits, and investments held by the company.
BrightSpring Health Services, Inc. Common StockNASDAQ: BTSG
Interest Income · Q3 FY2026 · quarter ended Sep 2026
Interest income remains negative
Q3 FY2026 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $0.
Context
- Interest income amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Interest income increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Interest Income vs competitors
How BTSG compares with its peers on the latest reported figures
- BTSG's LTM Sep 2026 interest income of $0 is the 2nd highest of the 4 companies compared; the peer median is $0.
- Interest income amounts to 0.0% of revenue for BTSG, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $7.29M | -36.6% | +191.0% | 0.3% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BTSG) | $0 | -36.6% | +191.0% | 0.0% | |
Competitors are the stored peer set for BTSG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.7B | 7.72B | 8.83B | 11.27B | 12.91B |
| Cost of Revenue | 5.45B | 6.37B | 7.39B | 9.68B | 11.39B |
| Gross Profit | 1.25B | 1.35B | 1.43B | 1.59B | 1.52B |
| Gross Margin | 18.6% | 17.5% | 16.2% | 14.1% | 11.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.01B | 1.13B | 1.29B | 1.38B | 1.22B |
| Operating Expenses | 1.01B | 1.17B | 1.29B | 1.38B | 1.22B |
| Depreciation & Amortization | 199.16M | 203.97M | 202.34M | 204.48M | 164.28M |
| EBITDA | 433.34M | 391.8M | 349.52M | 398.13M | 459.53M |
| EBITDA Margin | 6.5% | 5.1% | 4.0% | 3.5% | 3.6% |
| Operating Income | 234.18M | 187.83M | 147.18M | 206.37M | 295.25M |
| Operating Margin | 3.5% | 2.4% | 1.7% | 1.8% | 2.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 165.32M | 233.58M | 324.59M | 228.39M | 157.31M |
| Other Income / Expenses | (165.32M) | (233.58M) | (324.59M) | (241.11M) | (157.31M) |
| Income Before Tax | 68.86M | (45.75M) | (177.41M) | (34.74M) | 137.94M |
| Pre-Tax Margin | 1.0% | -0.6% | -2.0% | -0.3% | 1.1% |
| Income Tax Expense | 17.6M | 8.47M | (20.58M) | (14.22M) | 33.15M |
| Net Income | 49.8M | (53.91M) | (154.6M) | (18.06M) | 190.67M |
| Net Margin | 0.7% | -0.7% | -1.8% | -0.2% | 1.5% |
| EPS (Basic) | 0.29 | (0.31) | (0.90) | (0.09) | 0.94 |
| EPS (Diluted) | 0.29 | (0.31) | (0.90) | (0.09) | 0.87 |
| Weighted Avg Shares | 171.19M | 171.19M | 171.19M | 193M | 202.56M |
| Weighted Avg Shares (Diluted) | 171.19M | 171.19M | 171.19M | 193M | 219.77M |
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
Intrinsic Alpha fair value
Locked
Current Price
$68.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.